Effect of Institutional Experience on Outcomes of Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F18%3A10375411" target="_blank" >RIV/00216208:11130/18:10375411 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/18:00105231 RIV/00159816:_____/18:00068668 RIV/00064203:_____/18:10375411

Výsledek na webu

<a href="https://doi.org/10.1016/j.cjca.2017.10.020" target="_blank" >https://doi.org/10.1016/j.cjca.2017.10.020</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.cjca.2017.10.020" target="_blank" >10.1016/j.cjca.2017.10.020</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Effect of Institutional Experience on Outcomes of Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy

Popis výsledku v původním jazyce

Background: The current American College of Cardiology Foundation/American Heart Association guidelines on hypertrophic cardiomyopathy state that institutional experience is a key determinant of successful outcomes and lower complication rates of alcohol septal ablation (ASA). The aim of this study was to evaluate the safety and efficacy of ASA according to institutional experience with the procedure. Methods: We retrospectively evaluated 1310 patients with symptomatic obstructive hypertrophic cardiomyopathy who underwent ASA and were divided into 2 groups. The first-50 group consisted of the first consecutive 50 patients treated at each centre, and the over-50 group consisted of patients treated thereafter (patients 51 and above). Results: In the 30-day follow-up, there was a significant difference in the occurrence of major cardiovascular adverse events (21% in the first-50 group vs 12% in the over-50 group; P &lt; 0.01), which was driven by the occurrence of cardiovascular deaths (2.1% vs 0.4%; P = 0.01) and implanted pacemakers (15% vs 9%; P &lt; 0.01). In the long-term follow-up (5.5 +/- 4.1 years), the first-50 group was associated with a significantly higher occurrence of major adverse events (P &lt; 0.01) and higher cardiovascular mortality (P &lt; 0.01). Also, patients in the first-50 group were more likely to self-report dyspnea of New York Heart Association class III/IV (16% vs 10%), to have a left ventricular outflow gradient &gt; 30 mm Hg (16% vs 10%) at the last clinical check-up (P &lt; 0.01 for both), and a probability of repeated septal reduction therapy (P = 0.03). Conclusions: An institutional experience of &gt; 50 ASA procedures was associated with a lower occurrence of ASA complications, better cardiovascular survival, better hemodynamic and clinical effect, and less need for repeated septal reduction therapy.

Název v anglickém jazyce

Effect of Institutional Experience on Outcomes of Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy

Popis výsledku anglicky

Background: The current American College of Cardiology Foundation/American Heart Association guidelines on hypertrophic cardiomyopathy state that institutional experience is a key determinant of successful outcomes and lower complication rates of alcohol septal ablation (ASA). The aim of this study was to evaluate the safety and efficacy of ASA according to institutional experience with the procedure. Methods: We retrospectively evaluated 1310 patients with symptomatic obstructive hypertrophic cardiomyopathy who underwent ASA and were divided into 2 groups. The first-50 group consisted of the first consecutive 50 patients treated at each centre, and the over-50 group consisted of patients treated thereafter (patients 51 and above). Results: In the 30-day follow-up, there was a significant difference in the occurrence of major cardiovascular adverse events (21% in the first-50 group vs 12% in the over-50 group; P &lt; 0.01), which was driven by the occurrence of cardiovascular deaths (2.1% vs 0.4%; P = 0.01) and implanted pacemakers (15% vs 9%; P &lt; 0.01). In the long-term follow-up (5.5 +/- 4.1 years), the first-50 group was associated with a significantly higher occurrence of major adverse events (P &lt; 0.01) and higher cardiovascular mortality (P &lt; 0.01). Also, patients in the first-50 group were more likely to self-report dyspnea of New York Heart Association class III/IV (16% vs 10%), to have a left ventricular outflow gradient &gt; 30 mm Hg (16% vs 10%) at the last clinical check-up (P &lt; 0.01 for both), and a probability of repeated septal reduction therapy (P = 0.03). Conclusions: An institutional experience of &gt; 50 ASA procedures was associated with a lower occurrence of ASA complications, better cardiovascular survival, better hemodynamic and clinical effect, and less need for repeated septal reduction therapy.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

<a href="/cs/project/NV15-34904A" target="_blank" >NV15-34904A: Sekvenování nové generace k určení časné diagnózy a individualizované léčby hypertrofické kardiomyopatie</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Canadian Journal of Cardiology

ISSN

0828-282X

e-ISSN

—

Svazek periodika

34

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

7

Strana od-do

16-22

Kód UT WoS článku

000418674300007

EID výsledku v databázi Scopus

2-s2.0-85039940312